Takeda Announces Creation of One Cambridge Campus in Kendall Square to Drive Innovation Efforts

Takeda (TSE:4502/NYSE:TAK) today announced that it has signed a 15-year lease with BioMed Realty for approximately 600,000 square feet of research and development (R&D) and office space to be built at 585 Third Street in Kendall Square. The state-of-the-art facility will allow Takeda, the largest life sciences employer in Massachusetts, to create a purpose-built R&D facility with laboratories of the future featuring modern design elements and upgraded technology to support the company in its efforts to advance innovation for patients. The new facility will support Takeda’s efforts to redefine the future of work by adopting flexible workspaces to maximize in-person interaction and connection under a flexible and hybrid working model. The company will also expand its existing space in 650 East Kendall to include two additional floors, making Takeda the sole laboratory and office tenant in that building.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220621006010/en/

(Photo: Takeda)

The agreement with BioMed Realty further expands Takeda’s presence in Kendall Square, a hub for life sciences, and is part of the company's long-term strategy to create one Cambridge campus in Kendall Square, unifying Takeda’s Global R&D center in Cambridge and co-locating R&D with businesses and other operations. Takeda will eventually transition teams from Central Square to Kendall Square over time. Takeda will maintain a presence in Lexington as its suburban location.

“Takeda’s purpose to achieve ‘better health for people, a brighter future for the world’ is embedded into all of our decision-making, including real estate. We were intentional in selecting 585 Third Street as this building will offer us close proximity to top life sciences talent while enabling us to further enhance office collaboration and R&D space to support scientific discovery for patients worldwide,” said Julie Kim, President of the U.S. Business Unit and U.S. country head. “Our goal is to build an enriching and inclusive workspace that will inspire, foster learning and innovation, harness data and digital technologies and emphasize well-being.”

The new building is designed with sustainability in mind and will pursue LEED Gold or higher certification. And, as part of this innovative project, Takeda and BioMed Realty have identified shared goals and commitments around occupant wellness, energy and water efficiency, and reduced waste to landfills. Moving to 585 Third Street and expanding the presence in Kendall Square will help Takeda achieve its ambitious environmental goals including net-zero greenhouse gas emissions for scopes 1 and 2 before 2035, and for its entire value chain, including currently estimated¹ scope 3 GHG emissions, before 2040².

Takeda is committed to ensuring its footprint in Massachusetts reflects its ways of working with a focus on fostering sustainability, harnessing innovation and offering the best people experience while also creating cost efficiencies. Over the past several years, the company has been deepening its presence in Kendall Square. Construction of 585 Third Street is scheduled to begin in 2023 and Takeda plans to occupy the building starting in 2026. Takeda will ensure lab continuity and minimal disruption throughout the space planning and construction process.

About Takeda

Takeda is a global, values-based, R&D-driven biopharmaceutical leader headquartered in Japan, committed to discover and deliver life-transforming treatments, guided by our commitment to patients, our people and the planet. Takeda focuses its R&D efforts on four therapeutic areas: Oncology, Rare Genetics and Hematology, Neuroscience, and Gastroenterology (GI). We also make targeted R&D investments in Plasma-Derived Therapies and Vaccines. We are focusing on developing highly innovative medicines that contribute to making a difference in people’s lives by advancing the frontier of new treatment options and leveraging our enhanced collaborative R&D engine and capabilities to create a robust, modality-diverse pipeline. Our employees are committed to improving quality of life for patients and to working with our partners in health care in approximately 80 countries and regions. For more information, visit https://www.takeda.com.

Important Notice

For the purposes of this notice, “release” means this document, any oral presentation, any question and answer session and any written or oral material discussed or distributed by Takeda Pharmaceutical Company Limited (“Takeda”) regarding this release. This release (including any oral briefing and any question-and-answer in connection with it) is not intended to, and does not constitute, represent or form part of any offer, invitation or solicitation of any offer to purchase, otherwise acquire, subscribe for, exchange, sell or otherwise dispose of, any securities or the solicitation of any vote or approval in any jurisdiction. No shares or other securities are being offered to the public by means of this release. No offering of securities shall be made in the United States except pursuant to registration under the U.S. Securities Act of 1933, as amended, or an exemption therefrom. This release is being given (together with any further information which may be provided to the recipient) on the condition that it is for use by the recipient for information purposes only (and not for the evaluation of any investment, acquisition, disposal or any other transaction). Any failure to comply with these restrictions may constitute a violation of applicable securities laws. The companies in which Takeda directly and indirectly owns investments are separate entities. In this release, “Takeda” is sometimes used for convenience where references are made to Takeda and its subsidiaries in general. Likewise, the words “we”, “us” and “our” are also used to refer to subsidiaries in general or to those who work for them. These expressions are also used where no useful purpose is served by identifying the particular company or companies.

Forward-Looking Statements

This press release and any materials distributed in connection with this press release may contain forward-looking statements, beliefs or opinions regarding Takeda’s future business, future position and results of operations, including estimates, forecasts, targets and plans for Takeda. Without limitation, forward-looking statements often include words such as “targets”, “plans”, “believes”, “hopes”, “continues”, “expects”, “aims”, “intends”, “ensures”, “will”, “may”, “should”, “would”, “could” “anticipates”, “estimates”, “projects” or similar expressions or the negative thereof. These forward-looking statements are based on assumptions about many important factors, including the following, which could cause actual results to differ materially from those expressed or implied by the forward-looking statements: the extent to which our internal energy conservation measures and future advancements in renewable energy or low carbon energy technology will enable us to reduce our GHG emissions; the economic circumstances surrounding Takeda’s global business, including general economic conditions in Japan and the United States; competitive pressures and developments; changes to applicable laws and regulations, including global health care reforms; challenges inherent in new product development, including uncertainty of clinical success and decisions of regulatory authorities and the timing thereof; uncertainty of commercial success for new and existing products; manufacturing difficulties or delays; fluctuations in interest and currency exchange rates; claims or concerns regarding the safety or efficacy of marketed products or product candidates; the impact of health crises, like the novel coronavirus pandemic, on Takeda and its customers and suppliers, including foreign governments in countries in which Takeda operates, or on other facets of its business; the timing and impact of post-merger integration efforts with acquired companies; the ability to divest assets that are not core to Takeda’s operations and the timing of any such divestment(s); and other factors identified in Takeda’s most recent Annual Report on Form 20-F and Takeda’s other reports filed with the U.S. Securities and Exchange Commission, available on Takeda’s website at: https://www.takeda.com/investors/sec-filings/ or at www.sec.gov. Takeda does not undertake to update any of the forward-looking statements contained in this press release or any other forward-looking statements it may make, except as required by law or stock exchange rule. Past performance is not an indicator of future results and the results or statements of Takeda in this press release may not be indicative of, and are not an estimate, forecast, guarantee or projection of Takeda’s future results.

____________________

¹ A lack of transparency into, and a difficulty measuring, actual Scope 3 emissions remains an important challenge to overcome as part of these efforts.

² Takeda defines carbon neutrality and net zero emissions in accordance with The Greenhouse Gas Protocol. Additional information on our carbon neutrality efforts and other environmental sustainability programs is available at https://www.takeda.com/corporate-responsibility/reporting-on-sustainability/planet/.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220621006010/en/